Focus on Lipids Care

Back to articles

Rosuvastatin reduces cardiovascular events in older, healthy adults

KEY POINT

A retrospective subanalysis of data from JUPITER (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) showed that patients 70 years and older given rosuvastatin (Crestor—AstraZeneca) 20 mg/d for primary prevention had a 39% reduction in major cardiovascular events over a 2-year period compared with placebo; no differences in mortality were seen between groups.